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Alternative splicing of the precursor mRNA encoding for the neuropeptide receptor
PAC1/ADCYAP1R1 generates multiple protein products that exhibit pleiotropic activities.
Recent studies in mammals and zebrafish have implicated some of these splice isoforms
in control of both cellular and body homeostasis. Here, we review the regulation of PAC1
splice variants and their underlying signal transduction and physiological processes in the
nervous system.
Keywords: ADCYAP1R1, activity-dependent gene regulation, zebrafish model system, PACAP receptor, stress
disorders, post-traumatic, hypothalamic hormones, homeostasis
INTRODUCTION
G-protein-coupled receptors (GPCRs) represent the largest fam-
ily of membrane-associated proteins mediating physiological
responses in vertebrates by means of controlling metabolic, neural,
and developmental functions (Lefkowitz, 2007; Frooninckx et al.,
2012; Zhang and Eggert, 2013). These proteins are expressed in
almost all types of tissues and are represented by over 1,000 mem-
brane receptors for extracellular (EC) ligands including hormones,
neurotransmitters, pheromones, lipids, and other proteins (Xue
et al., 2008; Markovic and Grammatopoulos, 2009; Nordstrom
et al., 2009; Hoyer and Bartfai, 2012; Jafurulla and Chattopad-
hyay, 2013). The basic structure of GPCR proteins consists of a
seven-transmembrane (TM) domain with a complex EC structure
composed of an N-terminal region and three EC loops involved
in the diverse ligand recognition process. Three intracellular (IC)
loops and a C-terminal domain transduce a signal into the cell’s
cytoplasm and nucleus. Typically, ligand binding to the EC loops
induces conformational changes in the TM and IC domains of the
receptor resulting in specific coupling to a set of cytoplasmic mol-
ecules, termed G-proteins, each composed of different isoforms of
alpha, beta, and gamma subunits. G-proteins in turn regulate the
activity of IC effector molecules, including adenylate cyclase (AC),
phospholipase Cβ (PLC), and RhoGEF causing the activation of
secondary messengers such as cyclic AMP (cAMP), inositol-1,4,5-
triphosphate (InP3), and diacylglycerol leading to the initiation of
distinct IC signaling pathways (Simon et al., 1991; Sah et al., 2000;
Pierce et al., 2002; Oldham and Hamm, 2008; Mizuno and Itoh,
2009; Mahata et al., 2011; Maurice et al., 2011).
The diversity of the GPCR-initiated signal transduction path-
ways is determined by the multiplicity of cognate ligands
with different receptor binding properties and by the recep-
tors’ membrane-interacting partners that form homo- and
hetero-dimerized GPCR complexes. These receptor dimers have
unique binding properties to both EC ligands and a set of IC
G-proteins (Milligan and Kostenis, 2006; Harikumar et al., 2008;
Furness et al., 2012). Thus, ligand binding, along with receptor
heterodimerization, can generate diversity in G-proteins coupling
that can generate varied IC signaling functions.
Beyond the complexity of the aforementioned EC and IC
GPCRs interacting effectors, the genetic diversity of the GPCR
family can be generated by means of alternative precursor mRNAs
(pre-mRNA) splicing of exons encoding specific protein moieties
and causing considerable functional differences of the resulting
splicing products (Black, 2003; Jaillon et al., 2008; Furness et al.,
2012). Alternative splicing mechanisms allow the generation of
multiple mRNA transcript variants from a single gene by utilizing
different combinations of exons by means of skipping or inser-
tion of alternatively spliced exons. In particular, neuronal cells are
known to exhibit high levels of alternative splicing, generating the
basis for molecular and cellular diversity important for the pat-
terning and maintenance of the central and peripheral nervous
systems (Yeo et al., 2007; Betke et al., 2012; Norris and Calarco,
2012; Sun et al., 2012). In the case of GPCRs, this combinatorial
exon assembly can lead to changes in the protein domains respon-
sible for ligand binding, IC effector coupling, as well as receptor
stability, and endocytosis.
In this review we focus on one GPCR, the pituitary AC-
activating polypeptide (PACAP) receptor (ADCAYP1R1), also
known as PAC1. This receptor represents a fascinating example of
how alternative splicing of a single GPCR gene leads to different
physiological outcomes. We will describe the current knowledge
regarding the role and mechanism of action of PAC1 splice vari-
ants in development, physiology, and diseases focusing on PAC1’s
role in the nervous system.
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THE PAC1 RECEPTOR
PAC1 belongs to the glucagon/secretin receptor family of GPCRs
that consists of hormone and neuropeptide receptors. These
receptors signal through coupling to the G-protein alpha sub-
units Gs and Gq that typically activate AC and phospholi-
pase Cβ enzymes, respectively (McCulloch et al., 2002; Ahren,
2008; Dickson and Finlayson, 2009; Vallejo, 2009; Vaudry et al.,
2009). Coupling of PAC1 to Gs may also lead to cAMP-
dependent accumulation of IC calcium (Braas and May, 1996;
Mustafa et al., 2010). The PAC1 gene contains multiple exons
that undergo extensive alternative splicing. The peptide PACAP
is the high-affinity ligand for PAC1. Post-translational prote-
olytic processing of the PACAP precursor protein generates sev-
eral polypeptides with varying sizes, including PACAP38 and
PACAP27 (Miyata et al., 1989; Vaudry et al., 2009; Harmar
et al., 2012; Watkins et al., 2012). PAC1 was found to play a
pivotal role in the spatio-temporal regulation of proliferation,
differentiation, or cell survival during development as well as
in the regulation of synthesis and release of neuroendocrine
hormones.
Phylogenetic analysis of the vertebrate PAC1 receptor family
indicates their origin from a common ancestral gene and demon-
strates a tree topology with species-specific paralogs belonging to
different separated sub-groups (Figure 1). Bony fishes (teleosts)
genomes typically contain more than one gene due to teleost-
specific gene duplication event of both ligand and receptor mol-
ecules during the evolution of these species (Wei et al., 1998;
Fradinger et al., 2005; Bjarnadottir et al., 2006; Cardoso et al.,
2007; Machluf et al., 2011).
ALTERNATIVELY SPLICED PAC1 GENE PRODUCTS
The alternative splicing of PAC1 has been extensively studied. In
this review we use the exon numbers designation of the human
PAC1 and otherwise indicate cases where the exons numbers do
not match. The human gene was shown to contain 18 exons
with the open reading frame encoded by exons 2–18 (Chatterjee
et al., 1997; Lutz et al., 2006). Ten of these exons are constitu-
tively expressed (exons 2, 3, 7–13, 18), whereas the rest (exons
4–6, 14, 15, and possibly 16, 17) are regulated by the alternative
splicing (Figure 2). The N-terminal part of PAC1’s EC domain is
encoded by six exons. Exons 7–17 encode the seven-TM domains
including EC and IC loops and exon 18 encodes the C-terminal
cytoplasmic tail including the 3′-untranslated region (Figures 2
and 3). PAC1 splicing variants were identified in other verte-
brate species including rat, mouse, frog, and fish. In Table 1 we
assembled all known PAC1 splice isoforms from different ver-
tebrate species. The functional outcome of these splicing events
will be discussed later. By and large, PAC1 alternative splicing
can be divided into four types of splicing events that impact
receptor functions (Figure 3; Table 1): (1) Variations in the EC
N-terminal domain altering the ligand-binding specificity and
affinity. (2) Variations in exons encoding to part of the third IC
loop (IC3) thereby affecting G-protein coupling and/or interac-
tion with other IC signaling proteins. (3) Variations in the TM
domains TM2 and TM4 contributing to the receptors heteromer-
ization and IC transport. (4) Variations in the 5′ UTR that may
affect mRNA expression dynamics. Notably, splicing products
FIGURE 1 |Tree topology of the vertebrate PAC1 receptor family.
Phylogenetic relationships of PAC1 receptors analyzed using the zebrafish
(Danio rerio) Vpac1b gene as an out-group.
containing different combinations of N-terminal and IC3 splice
variants were identified in mammalian species.
The terminology used in independent studies can be some-
what perplexing as different names were designated to PAC1
isoforms corresponding to the same splicing events identified in
various species. In the following section we describe the various
splice variants and indicate when a different (i.e., specie-specific)
name was designated to the same isoform. A splice isoform that
includes all N-terminal encoding exons but does not contain IC
(IC3) insertion(s) is referred to as “PAC1-null” (Table 1). The
ligand binding and signaling properties of PAC1-null are often
used as a reference when assessing the activities of other splice
variants.
N-TERMINAL VARIATIONS
The N-terminal variants were identified in rodents and humans
but not in fishes to date. They are generated by alternative splic-
ing of exon 5 (PAC1-δ5), exons 5–6 (PAC1-short or PAC1-δ5,6),
or exons 4–6 (PAC1-very short or PAC1-δ4,5,6) leading to dele-
tions of 7, 21, or 57 amino acids, respectively (Journot et al., 1994;
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FIGURE 2 | A diagram showing genomic organization of the PAC1
(ADCYAP1R1) gene. Exons 2–18 encode the open reading frame. Exons
undergoing the alternative splicing discussed in this review are marked with
blue asterisks. Exon 4, 5, and 6 encode parts of the N-terminal domain,
whereas exons 14 and 15 encode the third intracellular loop. TM,
transmembrane.
Pantaloni et al., 1996; Chatterjee et al., 1997; Dautzenberg et al.,
1999; Lutz et al., 2006; Ushiyama et al., 2007, 2010). In the rat,
an insertion of 24 amino acids is caused by splicing of a novel
exon 3a located between exons 3 and 4 (PAC1-3a) (Figure 3)
(Daniel et al., 2001; Ajpru et al., 2002; Pilzer and Gozes, 2006a).
N-terminal splicing isoforms of PAC1 display alterations both
in ligand-binding selectivity and coupling to second messengers
compared to PAC1-null.
INTRACELLULAR LOOP VARIATIONS
PAC1 splice variants in the third IC loop (IC3) have been identified
in human, amphibian, fishes, and rodents. These splice isoforms
are characterized by the presence of one or two cassettes of 84
nucleotides (hip or hop1 variants) or 81 nucleotides (hop2 vari-
ant), or a combination of alternative spliced “cassettes” (hip-hop1
or hip-hop2) (Spengler et al., 1993; Journot et al., 1995; Grimaldi
and Cavallaro, 1999; McCulloch et al., 2001; Ronaldson et al.,
2002; Fradinger et al., 2005; Ushiyama et al., 2007; May et al.,
2010; Holighaus et al., 2011). In human, hip and hop variants are
also referred to as SV1 and SV2 or SV3 for hip-hop1 (Pisegna
and Wank, 1996; Pisegna et al., 1996). In addition, a splice variant
formed by a C-terminal deletion of 193 nucleotides (denoted“hop1
novel”) including two amino acids that are essential for G-protein
recognition was identified in rat cochlea samples (Abu-Hamdan
et al., 2006). Similar alternative splicing variants of PAC1 are also
found in non-mammalian vertebrates such as the frog and bony
fishes. Three alternative splice variants were identified in the frog
IC3 loop (Alexandre et al., 2002). PAC1-R25, with an insertion
of 25 amino acids, corresponds to the mammalian hop cassette.
PAC1-R41 contains a cassette with no homology to any other vari-
ant. PAC1-RMc with a unique cytoplasmic insertion of 13 amino
acid into the TM7 domain is missing a canonical Gs recognition
motif. PAC1 genes were also identified in zebrafish, goldfish, stick-
leback, fugu, sea bream, and several others bony fish species. Three
zebrafish PAC1 alternative splice variants with insertions in the IC3
loop were identified. Two of them were found to be homologous
to the hop1 (84 nucleotides) and hop2 (81 nucleotides) mam-
malian isoforms (Fradinger et al., 2005). A unique 107 nucleotides
inclusion with a premature stop codon (PAC1-skip) resulting in
a truncated PAC1 protein did not correspond to any previously
detected PAC1 isoform (Fradinger et al., 2005). This isoform
resembles an alternative splicing event in a human gene encod-
ing another secretin family receptor, VPAC1. Interestingly, the hip
cassette variant was not identified in the mouse and zebrafish
genomes. Moreover, teleosts genomes contain two (duplicated)
PAC1 paralogs, pac1a and pac1b, however, only pac1a encodes for
the hop splicing cassette.
TRANSMEMBRANAL DOMAIN VARIATIONS
A PAC1 variant, cloned from the rat cerebellum, has amino acids
deletion/substitution in the TM4 domain along with two amino
acid substitutions in the N-terminal (D136N) and TM2 (N190D)
domains (Chatterjee et al., 1996; Ajpru et al., 2002). The exact mol-
ecular mechanism underlying these variations remains unclear.
Notably, the TM4 domain of the secretin family receptors are
involved in homo- and hetero-oligomerization of these receptors,
associations with receptor activity-modifying proteins (RAMPs),
and with GPCR kinases (GRKs) thereby suggesting that splice
alterations in the PAC1-TM4 domain may affect receptor func-
tion (Morfis et al., 2003; Ritter and Hall, 2009; Magalhaes et al.,
2012).
5′ UTR VARIATIONS
Alternative splicing events in exons located at the 5′ UTR were
identified for rat PAC1 gene (Chatterjee et al., 1997). These include
different alternative usage of exons located upstream to the ATG
translation start codon. Such variations in the 5′ UTR organiza-
tion and sequences may play a role in the regulation of mRNA
expression.
ALTERNATIVE PAC1 SPLICING ALTERS LIGAND-BINDING
PROPERTIES
PAC1 is considered as being the high-affinity receptor for PACAP,
while it displays low binding affinity to the vasoactive intesti-
nal polypeptide (VIP) (Apostolakis et al., 2005; Vaudry et al.,
2009; Harmar et al., 2012). Alternative splicing of PAC1 results
in different protein products displaying different ligand-binding
properties that may result in changes in affinity and selectivity
(Table 1). Most studies use the PAC1-null (McCulloch et al., 2001;
Holighaus et al., 2011) isoform as a reference for PACAP and VIP
binding properties.
Modeling of ligand-receptor binding proposes that the C-
terminal part of the ligand PACAP binds to the N-terminus of
the PAC1 receptor and that the N-terminal part of PACAP binds
to the receptor’s EC loops and TM domains (Furness et al., 2012).
Consequently, alterations in the EC domain of PAC1 are predicted
to affect these ligand-receptor binding properties (Table 1). Thus,
PAC1-very short (a.k.a. PAC1-δ4,5,6), which lacks 57 amino acids
in the EC1 domain displays decreased affinity to PACAP27 and
PACAP38 but its affinity toward VIP remains the same (Journot
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FIGURE 3 | A scheme depicting the topology of the PAC1 receptor. The
relative location of amino acids encoded by PAC1 exons are depicted by
the blue and gray beads. Predicted PAC1 structural motifs known to be
involved in protein-protein interactions determining G-protein mediated
PAC1 signaling are marked on the protein diagram with regard to putative
motifs formed due to insertions of hop and hip cassettes into the IC3 loop
sequence. EC, extracellular loop; IC, intracellular loop; TM, transmembrane
domain.
et al., 1995; Pantaloni et al., 1996; Dautzenberg et al., 1999; Lutz
et al., 2006). The binding affinities for PACAP38 of the δ5, δ5,6
(a.k.a. short) splice isoforms appeared to be very similar to that
of PAC1-null, while δ5,6 isoform has increased affinity toward
VIP. The rat-specific PAC1-3a isoform containing a 24 residue
N-terminal insertion displays increased affinity to PACAP38 but
not to PACAP27 (Daniel et al., 2001; Pilzer and Gozes, 2006a). It
should be noted that in all of these examples, PACAP is still the
better ligand for PAC1 when compared with VIP (Table 1).
The hop1 and hip-hop1 splice isoforms retain similar bind-
ing properties to those of PAC1-null. In contrast, insertions into
the IC3 loop, namely hip- and hop2-cassettes lead to the eleva-
tion of VIP (Spengler et al., 1993; Pisegna et al., 1996; Pilzer and
Gozes, 2006b) and the diminution of PACAP binding affinities,
thereby suggesting that the alteration in IC3 causes an inside-out
conformational change.
Notably, binding analysis of alternative spliced isoforms, which
result from combined changes in the EC and IC protein domains
yields interesting results. Thus, a splice variant composed of PAC1-
short with the inclusion of hop1-cassette, displays similar PACAP
and VIP binding properties to that of PAC1-null and different
VIP binding properties than PAC1-short alone (Lutz et al., 2006;
Ushiyama et al., 2007, 2010). Another combined splice variant
composed of PAC1-δ5 or PAC1-δ5,6 together with the hip cassette
had different ligand-binding properties to that of PAC1, PAC1-δ5,
or PAC1-hip alone (Lutz et al., 2006) (Table 1). This imply that
the IC3 domain contributes to the association of PAC1 with its
cognate ligands.
These results may be explained by a model for agonist bind-
ing to the corticotropin-releasing hormone (CRH) receptor, which
belongs to the same GPCR sub-family of PAC1 (Dong et al., 2005).
According to this model the TM6 protein domain plays a struc-
tural role in ligand binding. Thus, insertions into IC3 loop, which
is located between TM5 and TM6 region may cause a conforma-
tional change in TM6 and possibility affect binding of PACAP and
VIP to the EC part of the receptor. A proof for this model awaits a
solved three-dimensional protein structural of the different PAC1
isoforms.
ALTERNATIVE PAC1 SPLICING ALTERS INTRACELLULAR
SIGNAL TRANSDUCTION
Ligand binding to PAC1 results in allosteric changes in the IC
docking sites for effector coupling. A variety of IC signal transduc-
tion cascades can be differentially transduced by multiple PAC1
splice variants with altered EC or IC protein domains (Figure 4)
(Arimura, 1998; Dickson and Finlayson, 2009; Vaudry et al., 2009;
Furness et al., 2012). The most studied pathways include coupling
of PAC1 to Gs and Gq proteins and activation of AC and phos-
pholipase Cβ PLCβ) which result in the respective stimulation of
production of cAMP and/or IP3 (Milligan and Kostenis, 2006;
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FIGURE 4 | A scheme depicting the current knowledge on PAC1-mediated
signaling cascades resulting in a variety of neuronal outcomes. PKA was
shown to induce ERK1/2 thereby contributing to PACAP neuroprotective
(Villalba et al., 1997; Vaudry et al., 2003; Falluel-Morel et al., 2006; Stumm
et al., 2007) and neurotrophic (Ravni et al., 2006; Botia et al., 2007; Monaghan
et al., 2008) functions. Action potential (AP) firing induces a CRCT1/CREB
mediated neuroprotective effect, presumably through NMDA receptor
activation and was shown to be initiated by PKA activation (Baxter et al.,
2011). NMDA receptor was also shown to be indirectly activated by PACAP
(Llansola et al., 2004) or cAMP/PKA signaling (Costa et al., 2009). PAC1/PKA
signaling controls cellular apoptosis through inhibition of potassium channels
(Mei et al., 2004; Castel et al., 2006; Pugh and Margiotta, 2006) or induction
of calcium channels (Pugh and Margiotta, 2006). PAC1/PKA-mediated
activation of ion channels leads to activity-dependent neuronal differentiation
and synaptic plasticity (Lee et al., 1999; Maturana et al., 2002; Grumolato
et al., 2003; Nishimoto et al., 2007). The tumor suppressor gene Lot1 known
as a negative regulator of neuronal precursor proliferation was shown to be
controlled by PAC1/cAMP/ERK signaling pathway (Fila et al., 2009).
PAC1/PKA-dependent phosphorylation of Tau is involved in the control of
granule cell migration during cerebellar development (Falluel-Morel et al.,
2006). PAC1-mediated cAMP/ERK-dependent neurite outgrowth was shown
to be regulated via a novel neuritogenic factor NCS (Emery and Eiden, 2012)
or Epac/ERK (Gerdin and Eiden, 2007) pathways. PAC1/Epac was shown to
regulate neuronal differentiation via activation of p38 kinase along with
mobilization of Ca2+ from intracellular stores (Ster et al., 2007) as well as
Epac/Rit-dependent pathway involving CREB signaling (Shi et al., 2006). PAC1
was demonstrated to induce Rit through TrkA/Shc/SOS signaling initiated by
Src activation via dual Gs/Epac and Gi stimulation (Shi et al., 2010). PACAP
also signals through Gq-linked PLC> IP3>Ca2+/DAG>PKC, and
PLD>phosphatidic acid (PA) pathways (Journot et al., 1994; Makhlouf and
Murthy, 1997; Dejda et al., 2006). PAC1 is a mediator of gene transcription,
neuronal differentiation, and synaptic development (Masmoudi-Kouki et al.,
2006; Vaudry et al., 2007; Andero and Ressler, 2012). As an example of
functional diversity caused by PAC1 alternative splicing two additional
PAC1-hop1 signaling pathways are presented on the scheme. They depict
PAC1-hop1/ARF dependent PLD activation (McCulloch et al., 2001) and
internalization-dependent engagement of PI3Kγ/Akt activation (May et al.,
2010). AC, adenylate cyclase; AGS, activator of G protein signaling; Akt,
serine-threonine protein kinase PKB; cAMP, cyclic adenosine monophosphate;
ARF, ADP(adenosine diphosphate) ribosylation factor; Caln, calcineurin; CaMK,
calcium calmodulin kinase; CBP, creb binding protein; CRCT1, cysteine-rich
C-terminal 1; CREB, cAMP responsive element-binding protein; DAG, diacyl
glycerol; Epac, exchange factor directly activated by cAMP; ERK, extracellular
signal-regulate kinase; G, guanine nucleotide-binding regulatory protein; IP3,
inositol-1,4,5-triphosphate; JNK, c-Jun oncogene N-terminal kinase 1; Lot1,
lost on transformation 1; NCS, neuritogenic cAMP sensor; NGF, nerve growth
factor; NMDAR, N -methyl-d-aspartate receptor; p38, p38 mitogen-activated
protein kinase; PA, phosphatidic acid; PI3K, phosphatidylinositol 3′ OH kinase;
PKA, protein kinase A; PKC, protein kinase C;PLC, phospholipase; Raf, B-Raf
proto-oncogene serine/threonine kinase;Ras, retrovirus-associated DNA
sequences; Rap1, Rit, small GTPases of the RAS oncogene family; Sos, son
of sevenless homolog 1; Src, sarcoma viral oncogen homolog; Tau,
neuron-specific microtubule-associated protein; TrkA, tropomyosin-related
kinase.
Couvineau and Laburthe, 2012) (Figures 3 and 4). In addition,
PAC1 was shown to regulate the level of IC Ca2+ in either G-
protein dependent or independent manners. The following section
reviews the role of PAC1 splice variants in the activation of the
above pathways as well as other non-canonical signaling cascades
(see also Table 1).
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AC AND PLCβ
When compared to the PAC1-null isoform, some alternative
spliced variants display altered mode of signaling. For example,
PAC1 isoform 3a, δ4,5,6 (a.k.a. very short), hip, hip-hop, δ5-hip,
and δ5,6-hip show reduction in the potency of agonists-mediated
cAMP and IP3 production (Spengler et al., 1993; Dautzenberg
et al., 1999; Parsons et al., 2000; Daniel et al., 2001; Germano
et al., 2004; Lutz et al., 2006; Pilzer and Gozes, 2006a; Holighaus
et al., 2011). Similarly, PAC-TM4, hop1 novel, δ5,6,14–17, skip,
and Rmc have lost their ability to stimulate cAMP and IP3 pro-
duction (Chatterjee et al., 1996; Daniel et al., 2001; Ajpru et al.,
2002; Alexandre et al., 2002; Fradinger et al., 2005; Abu-Hamdan
et al., 2006; Pilzer and Gozes, 2006a). Notably, all of the above
splice variants have modified or deleted IC3, TM, and C-terminal
protein domains that are known to be important for G-protein
binding (Chatterjee et al., 1996).
In some studies, PAC1-null displays very low or no activation of
PLCβ while PAC1-hop1 switches its mode of signaling from AC to
PLCβ (Spengler et al., 1993; DiCicco-Bloom et al., 2000; Nicot and
DiCicco-Bloom, 2001; Ronaldson et al., 2002; May et al., 2010).
For example, PAC1-hop1 was reported to mediate the activation
of both AC and phospholipase C signaling in cortical sympathetic
neuroblasts, while PAC1-null merely signals via AC stimulated
pathway (Braas and May, 1996; DiCicco-Bloom et al., 2000). Other
studies report that both isoforms display dual activation of AC and
PLCβ pathways, however the hop1 isoform has higher activation
of these pathways. Thus, analyses of SV1/hip and SV2/hop1 show
that these isoforms display increased coupling to cAMP and PLCβ,
respectively (Spengler et al., 1993; Pisegna and Wank, 1996; Lu
et al., 1998; Braas and May, 1999; Parsons et al., 2000; Nicot and
DiCicco-Bloom, 2001; Germano et al., 2004; Lutz et al., 2006; May
et al., 2010; Holighaus et al., 2011). The frog R25 and R41 isoforms
containing amino acid insertions into IC3 have higher activation
of cAMP compared to PAC1-null (Alexandre et al., 2002).
Consistent with the effect of IC3 loop insertions on ligand-
binding properties, hip- and hop2-cassettes conferred comparable
potency to induction of cAMP and IP3 accumulation by PACAP
and VIP but at the same time characterized by much lower efficacy
of this response (Spengler et al., 1993; Pisegna and Wank, 1996;
Pisegna et al., 1996; Ronaldson et al., 2002; Lutz et al., 2006). On
the other hand, PAC1-hip variant was shown to retain AC medi-
ated signaling but demonstrated impaired coupling to the PLCβ
pathway (May et al., 2010).
CA2+SIGNALING
The concentration of calcium ions (Ca2+) in the cytoplasm is
controlled by its uptake and release by specific transporter pro-
teins residing in the plasma membrane, the inner mitochondria
membrane, and the endoplasmic reticulum (ER) (Clapham, 2007).
PAC1-mediated Ca2+ signaling was shown to play important
roles in regulating neurotransmitter release, and neurotransmit-
ter receptors (Shioda et al., 1997; Taupenot et al., 1999; Germano
et al., 2009; Mustafa et al., 2010; Pugh et al., 2010; Amir-Zilberstein
et al., 2012; Smith and Eiden, 2012). The effects of PAC1 splice iso-
forms on the levels of cytoplasmic Ca2+ were reported in the cases
of PAC1-null hop1/2, δ5,6/short, 3a, and PAC1-TM4 (Table 1)
(Dautzenberg et al., 1999; Lutz et al., 2006; Mustafa et al., 2007,
2010; Nishimoto et al., 2007; Germano et al., 2009; Hansson et al.,
2009; Vallejo, 2009; Ushiyama et al., 2010; Holighaus et al., 2011).
PACAP is known to modulate both EC Ca2+ influx via voltage-
gated calcium channels (VGCC) and Ca2+ release from IC ER
stores through both IP3/PLCβ and AC pathways but also through
other signaling cascades (Tanaka et al., 1997; Shioda et al., 1998;
Grimaldi and Cavallaro, 1999).
PAC1-null was reported to modulate cytosolic Ca2+ mobiliza-
tion from both EC and IC stores (Shioda et al., 1997; Masmoudi
et al., 2003; Payet et al., 2003; Nishimoto et al., 2007). In acutely
dissociated rat melanotrophs, the increase of cytosolic Ca2+ was
dependent on the activation of non-selective cation channels
and the facilitation of voltage-dependent Ca2+ channels by PKC-
and PKA-dependent phosphorylation, respectively (Tanaka et al.,
1997). cAMP-dependent entry of EC calcium was also reported
in astrocyte cells (Vallejo, 2009). It was also suggested that PAC1-
null-mediated elevation of cytoplasmic Ca2+ levels in NG108-15
cells is due to IP3 receptor-mediated Ca2+ release from IC stores
(Holighaus et al., 2011).
The PAC1-hop1 variant is responsible for both Ca2+ mobi-
lization from IC stores and influx through voltage-gated Ca2+
channels in bovine chromaffin cells (Mustafa et al., 2007). Trans-
fection of PAC1-hop to the adrenomedullary pheochromocytoma
(PC12) cell line showed sustained IP3-mediated Ca2+ release from
IC stores and from store-operated Ca2+ entry (SOCE) (Taupenot
et al., 1999; Mustafa et al., 2007, 2010). In bovine adrenal chromaf-
fin cells, PAC1-hop was shown to mediate cytosolic Ca2+ release
from ryanodine/caffeine-sensitive Ca2+ stores that was not depen-
dent on either cAMP or IP3 generation (Tanaka et al., 1998; Payet
et al., 2003). Heterologous expression of the rat PAC1-hop1 but not
PAC1-hip variant in NG108-15 and PC12 cells leads to an increase
in IC Ca2+ concentration (Mustafa et al., 2007; Holighaus et al.,
2011). In both cell lines the response consisted of a rapid and
transient rise of Ca2+ reminiscent of IP3 receptor-mediated Ca2+
release from IC stores followed by a prolonged Ca2+ accumulated
from EC source.
When compared with PAC1-null, PAC1-hop1 was more potent
in Ca2+ elevation (Holighaus et al., 2011). However, follow-
ing overexpression in Chinese Hamster Ovarian cells, activation
of PAC1-null induced higher Ca2+ levels when compared with
activation of PAC1-hop1 (Ushiyama et al., 2010). PAC1-hop1
also mediated PACAP-induced Ca2+ release from ER and PKCγ
translocation to the nucleus and plasma membrane resulting in
the astrocytic differentiation (Nicot and DiCicco-Bloom, 2001).
Finally, stimulation of voltage-gated L-type or non L-type Ca2+
channels following initiation of PAC1-hop1 signaling was also
reported (Mustafa et al., 2010).
Somewhat limited data was reported with regards to Ca2+ sig-
naling via other PAC1 splice variants. Thus, δ5,6/short as well as
the PAC1 isoform containing combined “short” deletion in the
N-terminal EC1 domain along with hop1-cassette in the IC3 loop
exhibit PACAP-induced cytoplasmic calcium elevation (Ushiyama
et al., 2010). PAC1-3a was shown to induce Ca2+ accumulation
through coupling to Gs/cAMP rather than Gq/PLCβ pathway
(Pilzer and Gozes,2006a). PAC1-TM4 that was found to be inactive
when assayed for both cAMP and PLCβ activation but it displayed
elevation of Ca2+ in response to PACAP27. It was demonstrated
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that this effect involved the modulation of voltage-gated L-type
Ca2+ channels (Chatterjee et al., 1996).
Taken together, the apparent inconsistent results concerning
the mechanisms underlying the aforementioned Ca2+ signaling
events are most likely due to the different cellular systems (e.g., cell
types) employed by the above studies to analyze PAC1-mediated
IC Ca2+ changes.
OTHER TRANSDUCTION PATHWAYS
Signaling of PAC1 through interaction with cytoplasmic protein
partners, other than the canonical Gs and Gq, was reported mainly
in the case of the PAC1-hop1 isoform (McCulloch et al., 2001;
Ronaldson et al., 2002). Both PAC1-null and -hop1 proteins were
reported to activate phospholipase D (PLD). Although PAC1-null-
mediated PLD stimulation involved Gq/11>PLC>PLD pathway,
PAC1-hop1 was capable of activating PLD through direct binding
to ADP-ribosylation factor (ARF) (McCulloch et al., 2002; Dejda
et al., 2006).
EXPRESSION OF PAC1 SPLICE ISOFORMS IN THE NERVOUS
SYSTEM
Information on time- and region-specific distribution of PAC1
splice isoforms may shed light on how PAC1 gene products reg-
ulate a plethora of biological functions in developmental and
physiological processes (D’Agata et al., 1996; Waschek et al.,
2000; Waschek, 2003; Vaudry et al., 2009). The distribution of
PAC1 has been examined in many species using different tech-
niques that revealed widespread expression in different tissues,
including the nervous, cardiovascular, endocrine, immune, and
respiratory systems (Aino et al., 1995; Abu-Hamdan et al., 2006;
Gomariz et al., 2006; Molnar et al., 2008; Jolivel et al., 2009;
Shneider et al., 2010; Lugo et al., 2011; Buljan et al., 2012).
However, knowledge concerning the expression of PAC1 splice
variants is somewhat limited at it is mainly based on analyses of
isolated brain areas and/or primary cell cultures. The reported
changes in PAC1 receptor variant expression appear to be most
evident during development. We have summarized the existing
data concerning the expression of these variants by focusing
on expression in the nervous system of different mammalian
species.
The major mRNA isoform of PAC1 in the brain is PAC1-null,
which contains no splice deletions or insertions. PAC1-null is pre-
dominantly expressed in neurons residing in different brain areas
although it is also detected in glial cells of the cerebella cortex
and in activated astrocytes (Pilzer and Gozes, 2006b; Dickson and
Finlayson, 2009; Vaudry et al., 2009).
PAC1 variants with N-terminal deletions are well represented in
human fetal brain tissues and in five human neuroblastoma lines
(Lutz et al., 2006; Falktoft et al., 2009), thereby suggesting their
role in immature nervous tissue. N-terminal splice variants were
detected in different brain areas. The PAC1-short variant with
21 amino acids N-terminal deletion was predominantly found
in the thalamus, hypothalamus, and the hypophysis, and more
moderately in the amygdala and retina (Dautzenberg et al., 1999;
Grimaldi and Cavallaro, 1999; Jamen et al., 2002; Girard et al.,
2004; Lutz et al., 2006; Ushiyama et al., 2007, 2010; Hammack
et al., 2010a). It was shown to be expressed in cochlea subfractions
along with the PAC1-δ5 isoform with a seven amino acid dele-
tion (Abu-Hamdan et al., 2006). The PAC1-very short variant (57
amino acid deletion) was also detected at low levels in the mouse
amygdala and cortex though not in the retina. All three N-terminal
variants (null, short, and very short) were abundantly expressed
in neuronal tissues (Dickson and Finlayson, 2009; Vaudry et al.,
2009). The PAC1-3a variant containing N-terminal insertion of
24 amino acids was detected in rat cerebral cortex. This splice iso-
form is also highly expressed in distinct cell populations of the
testis, including Sertoli cells, pachytene spermatocytes, and round
spermatids (Daniel et al., 2001; Ajpru et al., 2002; Pilzer and Gozes,
2006a).
Contrary to the aforementioned N-terminal splice variants that
were only reported in mammals, IC loops (i.e., IC3) splice prod-
ucts are found in all studied vertebrate species. In the postnatal
cerebral cortex of rats, the expression of PAC1-null, hop1, hip, and
hip-hop1 dramatically decreases during the first neonatal month
suggesting a major role for these isoforms in embryonic develop-
ment (Shneider et al., 2010). Interestingly, the expression of these
isoforms was shown to be gender dependent displaying higher
levels in female postnatal brain at least during the first 3 months
of development. In the developing retina, the proportion of IC3
PAC1 isoforms changes as development proceeds: PAC1-hip-hop1
transcript demonstrated transient elevation at day P10, while a
decrease in PAC1-null and hip along with elevation of PAC1-
hop1 level was observed by P20 (Lakk et al., 2012). PAC1-hop1
expression was found in the olfactory bulb, hippocampus, cerebral
cortex, cerebellum, and striatum of newborn rats. PAC1-hop2 was
present in rat cerebral astrocytes from newborn brains, in neuronal
enriched cultures, and in PC12 cells that undergo neuronal differ-
entiation following NGF treatment (Jamen et al., 2002; Onoue
et al., 2002; Hashimoto et al., 2003; Ravni et al., 2006; Mustafa
et al., 2010).
PAC1-hip was detected at much lower levels in adult tis-
sues and it was therefore speculated to be important for the
embryonic development (Shneider et al., 2010; Holighaus et al.,
2011). The relative expression of human and rat PAC1 splice
variants in the frontal cortex was reported to have the following
expression level hierarchy: null> SV1/hip> SV2/hop= SV3/hip-
hop (Pisegna and Wank, 1996; Pisegna et al., 1996; Germano et al.,
2004; Lutz et al., 2006). PAC1-hop1 was found to be expressed in all
neuroendocrine cells, suggesting a fine tuning of PAC1-mediated
signaling in the neuroendocrine cells (Mustafa et al., 2010). PAC1-
hop1 splice isoform was the major form expressed in the superior
cervical ganglia (SCG) sympathetic neurons, which also express
PAC1-short (Braas and May, 1999). Zebrafish IC3 splice isoforms
are widely expressed in the adult tissues with PAC1-hop1 detected
in brain and testis, PAC1-hop2 in the ovary and PAC1-skip vari-
ant in the gills (Fradinger et al., 2005). Lastly, although PAC1-TM4
isoform is mainly found in pancreatic β-cells it is also expressed in
the cerebral cortex, cerebellum, and brain stem (Chatterjee et al.,
1996; Ajpru et al., 2002).
In summary, changes in PAC1 receptor variant expression
appear to be most evident during development. The fact that PAC1
splice variants display differential expression patterns in the ner-
vous system suggests that alternative splicing of this gene product
plays a role in fine tuning of PAC1 activity in these areas.
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REGULATION OF PAC1 SPLICING BY NEURONAL-SPECIFIC
RNA-BINDING PROTEINS
The regulation of PAC1 splicing is not well understood. Alter-
native splicing of pre-mRNA is often regulated by conserved
cis-regulatory RNA sequence elements that serve as recognition
sites for different splicing factors. These RNA-binding splicing fac-
tors differ from the general spliceosome machinery proteins due
to the formers’ ability to either activate or repress the inclusion
of alternatively spliced exons, depending on whether the factors’
binding site is located upstream, downstream, or inside the exon.
Neuronal-specific splicing factors include nova-1/2, Rbfox-1/2,
and ELKV2 splicing factors, the neuronal-specific polypyrimidine
tract-binding protein (nPTB) as well as a set of heterogeneous
nuclear ribonucleoproteins (hnRNP A1,L,F.H1). As the consen-
sus cis-acting binding sequences for the aforementioned splicing
factors have been identified, their involvement in regulating the
alternative splicing of a given gene by sequence analysis can be pre-
dicted. We analyzed the presence of known consensus binding sites
for the following RNA-binding proteins: Rbfox-1/2,Nova-1/2 (sin-
gle and repeatedly organized elements), SC-35, nPTB enhancers
and silencers, and CaRRE for Ca2+/CaM kinase IV recognition
sequences. Putative binding sites for neuronal-specific splicing fac-
tors in the respective PAC1 genes of human, mouse, and zebrafish
are shown in Figure 5.
FIGURE 5 | Regulation of PAC1 splicing. (A) A chart depicting the
predicted binding sites for neuronal-specific RNA-binding proteins
that potentially regulate PAC1 gene splicing by binding in proximity
to PAC1 exons. Consensus cis-acting binding DNA elements for the
respective RNA-binding protein are depicted with respect to their
position in the PAC1 genes of rat, mouse, human, and zebrafish
PAC1. We analyzed the presence of putative consensus binding
sites located within 300 base-pairs upstream (upst) or downstream
(dnst) and inside the exons. (B) Schematic representation of the
PAC1 gene in which the location of the analyzed cis-acting elements
is color-coded as above. Corresponding exons numbers and sizes
(bp) are indicated.
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Rbfox-1/2 can act either as a splicing enhancer or as an inducer
of exon skipping (Zhang et al., 2008). Putative Rbfox-1/2 binding
sites located within a short distance downstream of target exons
are predicted to induce exon inclusion whereas upstream bind-
ing sites are predicted to cause exon skipping. Such Rbfox-1/2
recognition element located within a short distance downstream
of hop1 encoding exon has been experimentally validated as a
genuine Rbfox-1 binding site (Lee et al., 2009). Our own PAC1
bioinformatic analysis identified a putative Rbfox-1/2 binding ele-
ment within −30 nucleotides downstream from conserved exon
spanning zebrafish TM7 suggesting that this domain might be
regulated by alternative splicing (Figure 5). Rbfox-1/2 motifs
are also present in the sequences of all examined species down-
stream of exon 16 encoding parts of the TM7 domain. Another
recognition site is located upstream of exon 4 consistent with
a deletion of the exon resulting in the generation of PAC1-very
short splice variant (Figure 5). Rbfox-1/2 recognition motif pre-
dicts potential deletion of exon 8 that may result in a generation of
a soluble PAC1 receptor as in the case of the CRH receptor (Zmi-
jewski and Slominski, 2009, 2010). Rbfox-1/2 binding site is also
detected downstream of exon 11, which is known to encode the
most hypervariable amino acid sequence among Secretin family
GPCRs,as well as part of TM4 domain which undergoes alternative
splicing in PAC1-TM4 isoform (Markovic and Grammatopoulos,
2009).
Calcium signaling plays an important role in neuronal devel-
opment and is involved in the regulation of immediate and
long-term neuronal responses to various stimuli such as stressors
and hormones (Ghosh et al., 1994; West et al., 2001). Depo-
larization is known to be critical for modulating the neuronal
activity that induces Ca2+-dependent gene regulation, includ-
ing alternative splicing. Ca2+-dependent splicing is mediated by
L-type calcium channels and by Ca2+/calmodulin-dependent pro-
tein kinases IV (CaMK IV) (Lee et al., 2007, 2009). The latter
was shown to repress splicing of target genes containing spe-
cific recognition elements (CaRRE) located within the 3′ splice
site or inside the exon. Our own analysis detected additional
putative CaRREs that can be responsive to CaMK IV. We pre-
dicted single, multiple, and tandemly organized CaRRE repeats
upstream of exon 15 and 17 of the zebrafish, human, and mouse
PAC1 receptors, suggesting the involvement of CaMK IV in reg-
ulating the alternative splicing of these exons. Putative CaRREs
are also present proximal to mouse, rat, and zebrafish exon 4
(Figure 5).
Exonic and intronic hnRNPA1 and nPTB cis-elements that are
important for activity-dependent splicing in neuronal cells were
shown to repress the inclusion of target exons (Allemand et al.,
2005; An and Grabowski, 2007; Donev et al., 2007; Resnick et al.,
2008; Zheng et al., 2012). Putative hnRNPA1 and nPTB recogni-
tion sites are located proximal to exons 4, 5, and 6 consistent with
the known deletions of these exons that result in the generation
of PAC1-short and very short splice variants. Putative hnRNPA1
recognition motifs are also found near exons 8–10 encoding to
IC1, IC2, and EC2 domains (Figure 5).
Nova-1/2 regulates target exon inclusion or skipping with broad
distribution of binding sites across the gene sequence (Ule et al.,
2005; Yano et al., 2010; Norris and Calarco, 2012). Predicted
Nova-1/2 recognition elements are found in human and mouse
PAC1 and in both paralogs of zebrafish PAC1 gene (1a and 1b).
Interestingly, higher frequency of putative splicing-inducing AU-
rich and Nova-specific sequences are found in intronic regions
upstream of alternative spliced exons characteristic of the Secretin
family splicing patterns, e.g., around exon 4, 8, 9, 10 (Zmijew-
ski and Slominski, 2009) as well as exon 17. Exons 4–6 encode
sequences covering known N-terminal PAC1 deletion regions
(deletions of 7, 21, and 57 amino acids). Exon 17 encodes the
last amino acids of the seventh TM domain and the beginning of
the IC tail shown to represent the highly conserved exon within
the secretin family (Markovic and Grammatopoulos, 2009). Skip-
ping of this exon was not detected in the PAC1 receptor gene,
but it has been proposed that such exon skipping in the human
CRF1 and PTH1 receptors results in a six TM receptor displaying
impaired trafficking (Shyu et al., 1996; Grammatopoulos et al.,
1999; Markovic et al., 2008). The rabbit calcitonin receptor is also
formed as a result of the skipping of the TM7 domain and dis-
plays slightly diminished cAMP activation along with deficiency
in IP3 induction (Shyu et al., 1996). Taken together the above
analysis of potential cis-elements spanning TM7 exons predicts
that a PAC1 splice variant containing TM7 skipping may exist in
neuronal tissues.
An important question raised in this chapter is whether
the aforementioned RNA-binding factors regulate PAC1 splic-
ing in vivo. It has been demonstrated that alternative splicing
of the PAC1 receptor is regulated by the Rbfox-1 splicing fac-
tor in depolarized neurons. In this case, neuronal depolarization
induced CaM-kinase dependent self-splicing of Rbfox-1, lead-
ing to the translocation of Rbfox-1/2 from the cytoplasm to
the nucleus where Rbfox-1 could mediate the alternative splic-
ing of neuronal-specific target genes, including PAC1. Interest-
ingly, Rbfox-1 mRNA levels were shown to be regulated by the
Orthopedia (Otp) homedomain-containing protein. The latter
is a hypothalamic-specific transcriptional factor, which plays a
role in hypothalamic neuronal-specification during development
and in regulation of body homeostasis in the mature zebrafish
brain (Acampora et al., 1999; Wang and Lufkin, 2000; Blechman
et al., 2007; Ryu et al., 2007; Amir-Zilberstein et al., 2012; Fer-
nandes et al., 2012). The involvement and regulation of other
neuronal-specific RNA-binding factors in PAC1 splicing remains
to be determined.
PLEIOTROPIC ROLES OF PAC1 SPLICE ISOFORMS IN THE
NERVOUS SYSTEM
The distribution of PAC1 and its ligands PACAP and VIP in a
variety of cell types is reminiscent of the pleiotropic functions
of PAC1 in development and physiology. PACAP is described
in the literature as a hormone, neuropeptide, endocrine peptide,
neurotransmitter, and neurotrophic factor. It affects the central
nervous system (CNS), cardiovascular system, pituitary, thyroid,
and adrenal glands and provides functional activities in the gonads,
gastrointestinal tract, and pancreas (Waschek et al., 2000; Dick-
son and Finlayson, 2009; Vaudry et al., 2009). In the nervous
system, PAC1 was shown to affect a variety of hormones and
neuropeptides, including stimulation of oxytocin (Jamen et al.,
2003) and melatonin (Nakahara et al., 2002) release and de novo
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mRNA synthesis of CRH (Nakahara et al., 2002; Amir-Zilberstein
et al., 2012), arginine-vasopressin (Murase et al., 1995; Gillard
et al., 2006), GnRH (Kanasaki et al., 2009; Winters and Moore,
2011), somatostatin (Kageyama et al., 2007), and MSH (Mounien
et al., 2006). This overabundance of PAC1-mediated physiological
activities can be made possible through the signaling diversity of its
alternatively spliced gene products. Moreover, different expression
of PAC1 isoforms is common in neuronal ontogeny. Such differ-
ences in the expression of PAC1 splice variants might modulate
final outputs of VIP and PACAP activities as neurotransmitters,
neurotrophic, or differentiation factors. Examples for the involve-
ment of PAC1 splice isoforms in mediating these activities are
described below.
NEUROGENESIS, NEUROPROTECTION, AND DIFFERENTIATION
Neural progenitor cells (NPC) and astroglial cells express PAC1-
null and PAC1-hop1 variants that mediate both cAMP- and Ca2+-
dependent signaling pathways and induce production of a subset
of neurotrophic factors resulting in neuronal proliferation and/or
differentiation. PAC1-hop2 variant, detected in astrogenic and
neuronal populations, promote neuroprotective function induced
by VIP. In another study, VIP was also demonstrated to induce
PAC1-hop2-mediated astrocytes neuroprotection against oxida-
tive stress. Astrocytic expression of PAC1-hop2 isoform may there-
fore play a critical role in the NPC shift toward neuronal or
astrocytes differentiation (Ashur-Fabian et al., 1997; Pilzer and
Gozes, 2006b).
Expression of PAC1-null and PAC1-hop1 define region-specific
neurogenesis in the CNS and peripheral nervous systems (Lu et al.,
1998). Both variants are differently expressed in proliferating sym-
pathetic (PAC1-hop1) and cortical precursors (PAC1-null) reveal-
ing opposing PACAP-mediated mitogenic regulation – either by
stimulating sympathetic neuroblast proliferation or by inhibit-
ing cortical precursor mitosis. Ectopic expression of PAC1-hop1
in cortical neuroblasts may transform the anti-mitotic effect of
PACAP into promitotic. This promitotic signaling was shown to
involve PLC signaling pathway (Nicot and DiCicco-Bloom, 2001).
PAC1-hop1 was also shown to promote sympathetic neurons
survival following growth factor withdrawal (May et al., 2010).
In conjunction with the abovementioned, PACAP may pos-
sess therapeutic potential for neurodegenerative pathologies, such
as Parkinson’s and Alzheimer’s disease (AD). PACAP is enriched
in rat mesencephalic dopaminergic neurons and protects them
from neurotoxin-induced death (Reglodi et al., 2004). PACAP
was shown to be downregulated in several mouse models for
AD as well as in the human temporal cortex of AD patients
(Kojro et al., 2006; Rat et al., 2011; Postina, 2012). Amyloido-
genic processing of the amyloid precursor protein (APP) to
αβ-peptides is responsible for the development of AD. How-
ever, non-amyloidogenic APP processing pathway results in the
α-secretase-dependent cleavage within the αβ-peptide region, pre-
venting AD pathology. Continual PACAP and PAC1 activation
resulted also in a feed-forward autocrine elevation of both PACAP
and PAC1 in mice that may further facilitate non-amyloidogenic
APP cleavage. α-secretase activation was shown to be regulated
by ERK1 and ERK 2 and PI-3 kinase, suggesting that PAC1-
hop1 is the most efficient isoform with regard to the activation
of these downstream PLC effectors (Kojro et al., 2006; Rat et al.,
2011; Postina, 2012). It remains to be determined whether spe-
cific PAC1 splice variants are involved in these neuroprotective
activities.
NEUROSECRETION AND NEUROTRANSMISSION
Pituitary AC-activating polypeptide was shown to elicit cate-
cholamine synthesis and release. Expression of PAC1-hop1 in
bovine chromaffin NG108-15 cell line, which lacks endogenous
PAC1 receptors, induces the release of norepinephrine via a Ca2+
influx-dependent mechanism (Mustafa et al., 2007). Transfected
PAC1-hop1 triggers sustained catecholamine secretion by regulat-
ing Ca2+ levels through both ER and EC Ca2+ channels (Mustafa
et al., 2010; Smith and Eiden, 2012). Moreover, acute and long-
term met-enkephalin secretion and enkephalin biosynthesis were
attributed to bovine chromaffin cells upon PAC1-hop1-mediated
activation of L-type Ca2+ channels. This implies a role of hop1
splice cassette in regulating neuroendocrine secretion. SCG sym-
pathetic neurons were shown to predominantly express the PAC1-
hop1 splice isoform and PACAP stimulates neuropeptide Y release
in these neurons via a mechanism involving both AC and PLCβ
(Braas and May, 1999).
ROLE OF PAC1 SPLICE ISOFORMS IN BODY HOMEOSTASIS
PAC1 is implicated in the regulation of homeostatic processes,
including food and liquid consumption (Nomura et al., 1997;
Mounien et al., 2006, 2009), sleep (Hannibal and Fahrenkrug,
2004), stress (Pilzer and Gozes, 2006b; Amir-Zilberstein et al.,
2012), locomotion (Vaudry et al., 2000), memory and learning
activities (Dong et al., 2010; Andero and Ressler, 2012; Holighaus
et al., 2012), and circadian functions (Ajpru et al., 2002; Hannibal
and Fahrenkrug, 2004). Recent studies have indicated that at least
some of these activities are modulated by alternative splicing of
PAC1 (Ajpru et al., 2002; Hannibal and Fahrenkrug, 2004; Pilzer
and Gozes, 2006b; Holighaus et al., 2011, 2012; Amir-Zilberstein
et al., 2012).
Pituitary AC-activating polypeptide/PAC1 signaling was
recently implicated in abnormal stress responses underlying post-
traumatic stress disorder (PTSD) pathology (Ressler et al., 2011;
Andero and Ressler, 2012; Hauger et al., 2012). PACAP38 lev-
els in females were strongly associated with PTSD symptoms.
Ressler et al. and May et al. (2010) found that a single nucleotide
polymorphism (SNP), rs2267735 in the PAC1 gene is corre-
lated with PTSD in a gender-specific estrogen-dependent man-
ner. This SNP, which resides in the putative estrogen response
element within PAC1’s promoter/enhancer is associated with sex-
dependent PTSD, fear discrimination, PAC1 mRNA expression,
and methylation of PAC1. Using mouse models, these authors
showed that PAC1 mRNA was induced by fear conditioning or
estrogen hormone replacement in the bed nucleus of stria termi-
nalis (BNST), which is a component of the extended amygdala
involved in fear- and anxiety-like responses.
In connection to the above, steroid-induced changes in PAC1
splice isoforms were demonstrated in the case of PAC1-hop2
(Apostolakis et al., 2005). PAC1-hop2 and the N-terminal PAC1-
short splice variants were detected in the hypothalamic ventrome-
dial nucleus (VMN) upon estradiol or dual estradiol/progesterone
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treatment. The ratio of PAC1-hop2 mRNA to other PAC1 variants
in VMN depends on steroid application, implying its impor-
tance for cumulative PAC1 isoforms expression and hence sig-
naling properties. PACAP-induced sexual/mating behavior in
female rats was dependent on progesterone receptor in the
VMN. Estradiol stimulates synthesis of progesterone, which in
turn facilitates PACAP synthesis and activation of PAC1-short
and -hop2 signaling critical for the induction of animal sexual
receptivity.
PAC1 signaling is known to be required for physiological
stress response as activation of PAC1 by PACAP is required for
stress-induced CRH transcription in vivo and in vitro (Agar-
wal et al., 2005; Kageyama et al., 2007; Hammack et al., 2010b;
Stroth and Eiden, 2010; Tsukiyama et al., 2011). The above stud-
ies suggest that PAC1 splice variants and their relative expression
ratio might be involved in the regulation of body homeosta-
sis including physiological responses to stressor challenges. A
recent study performed in our lab, employed various stress par-
adigms in mouse and zebrafish to demonstrate that activation
and termination of CRH transcription caused by stressful stim-
uli is regulated by an interrelationship of PAC1-null and hop1
isoforms (Amir-Zilberstein et al., 2012). Thus, the generation
of PAC1-hop1 by alternative splicing leads to the termination
of CRH transcription, normal activation of the hypothalamic-
pituitary-adrenal axis, and adaptive anxiety-like behavior (Amir-
Zilberstein et al., 2012). We therefore suggested that alternative
splicing of the hop1-cassette serves as an ON/OFF stress switch
(Figure 6).
PAC1 rs2267735 gene polymorphism is also associated with
increased dark-enhanced startle (DES) in adult females but not
males with PTSD (Ressler et al., 2011). Moreover, children of
abused mothers show elevated DES and the same PAC1 gene
polymorphism associated with PTSD risk in adult females is also
associated with increased DES in these children (Jovanovic et al.,
2011, 2012). Notably, zebrafish larvae show a strong aversion to the
dark side of a two-compartment light/dark arena and this place
preference can be mitigated by anxiolytic drugs, such as Diazepam,
indicating that this assay measures an anxiety-like behavior (Steen-
bergen et al., 2011; Schnorr et al., 2012). We found that during the
recovery phase that follows a stressful challenge (osmotic shock),
wild type larvae decrease their dark-avoidance time, a pheno-
type indicative of decreased stress-related anxiety, while larvae
with depleted PAC1a-hop1 display delayed dark-avoidance recov-
ery (Amir-Zilberstein et al., 2012). Thus, the delayed behavioral
response of PAC1a-hop1-depleted embryos correlates with their
respective failure to terminate crh and cortisol levels following
stressors.
CONCLUSION
Alternative splicing is a major gene regulatory process involving
cis- and trans-acting factors. PAC1 signaling controls a variety
of cellular and physiological responses, such as differentiation,
proliferation, cell cycle regulation, neurotransmitter, and hor-
mone release and adaptation to stressful challenges. The PAC1
gene encompasses a relatively long genomic region, which con-
sists of up to 18 exons and contains many putative splicing
FIGURE 6 | A model illustrating the role of alternative splicing of PAC1
hop cassette that serves as an ON/OFF stress switch. In response to
various stressors, the so called PAC1-null splice variant (i.e., no deletion in
the N-terminal domain and no addition to the intracellular loops) modulate
transcriptional activation of CRH and stress behaviors to adapt to the
changes in homeostasis. Termination of CRH-mediated stress response is
mediated by means of regulation of PAC1 gene splicing and inclusion of an
altered exon (hop1) encoding to 28 amino acids of the third intracellular
loop leading to the formation of the PAC1-hop1 splice variant. Generation of
the PAC1-hop isoform terminates stress response by means yet to be
uncovered (see text and Amir-Zilberstein et al., 2012).
factors recognition sites that might be activated during dif-
ferent phases of neuronal activation. PAC1 receptor signaling
can be fine-tuned by the generation of a set of alternatively
spliced variants produced in a spatio-temporal manner. Splicing-
dependent alterations in PAC1 protein domains modify its lig-
and binding and signaling properties leading to a range of cel-
lular activities. Although the physiological function(s) of the
vast majority of the alternatively spliced PAC1 gene products
is still unknown, recent studies have implicated certain PAC1
splice variants in the regulation of homeostatic processes such
as adaptation to stressful challenges. In view of the recent associ-
ation of PAC1 with PTSD risk, the regulation of PAC1 splicing
and its underlying physiological outcomes might prove to be
relevant to the etiology of some neurological and psychiatric
disorders.
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